Skip to main content
. 2020 Jan 15;48(1):0300060519893496. doi: 10.1177/0300060519893496

Table 1.

Basic clinical characteristics and incidences of cytokine release syndrome and complications in all patients.

Variable Value
Age, years 55.1 ± 8.2 (50–72)
Sex, male:female 14:2
Course of disease, months 5.5 (3–18)
Treg cell number 1.41 ± 0.3 × 108
ISS stage, n (%)
 I 3 (18.8)
 II 7 (43.8)
 II 6 (37.5)
CRS stage, n (%)
 I 3 (18.8)
 II 9 (56.3)
 III 2 (12.5)
 IV 2 (12.5)
Complication, n (%)
 Hyperthermia 15 (93.8)
 Increase of inflammatory factors 13 (81.3)
 Muscle pain 11 (68.8)
 Headache 9 (56.3)
 Nausea 8 (50.0)
 Vomiting 5 (31.3)
 Diarrhea 3 (18.8)
 Renal impairment 3 (18.8)
 Liver impairment 1 (6.3)
 Neurological impairment 1 (6.3)
Drugs used before study, n (%)
 Lenalidomide 9 (56.3)
 Dexamethasone 12 (75.0)
 Bortezomib 7 (43.8)
 Adriamycin 6 (37.5)

ISS, International Staging System; CRS cytokine release syndrome.